KDEV Share Price | Karolinska Development AB Stock Analysis & Recommendation

Price Point

High/Low

1Day

52 Week

Valuation

Technical

Day's Volume

CASH

977.54 k

Shareholding (Dec 2014)

FII

0.02%

Held by 1 FIIs

DII

99.98%

Held by 0 DIIs

Promoter

0.00%

Compare Karolinska Development AB with Similar Stocks

Arbona AB Idun Industrier AB VEF AB

Score

Click here to find our call on this stock

Strong Sell

Sell

Hold

Buy

Strong Buy

MarketsMojo — Loved in India, Now Global

The power of Mojo is now in 29 countries. Explore global equities with the same cutting-edge features you love.Unlock 29 Markets

Dashboard

Weak Long Term Fundamental Strength with a -148.31% CAGR growth in Operating Profits

Risky -

Consistent Underperformance against the benchmark over the last 3 years

Mojo Parameters

Stock DNA

Industry

Finance

Market cap

SEK 98 Million (Micro Cap)

P/E

NA (Loss Making)

Industry P/E

Dividend Yield

0.00%

Debt Equity

-999,999.00

Return on Equity

-0.75%

Price to Book

0.09

Revenue and Profits:

Net Sales:

2 Million

(Quarterly Results - Sep 2025)

Net Profit:

-67 Million

Total Returns

Total Returns (Price + Dividend)

TimePeriod

Price Return

Dividend Return

Total Return

3 Months

-61.93%

6 Months

-68.12%

1 Year

-70.44%

2 Years

-81.3%

3 Years

-84.16%

4 Years

-92.06%

5 Years

-81.04%

Karolinska Development AB for the last several years.

Risk Adjusted Returns v/s

News & Corporate Actions

News

No Recent News for the Company

Announcements

No announcement available

Corporate Actions

No corporate action available

Key Factors

Quality key factors

Factor

Value

Sales Growth (5y)

-42.50%

EBIT Growth (5y)

-148.31%

EBIT to Interest (avg)

-16.57

Debt to EBITDA (avg)

Negative Net Debt

Net Debt to Equity (avg)

Sales to Capital Employed (avg)

Tax Ratio

Dividend Payout Ratio

Pledged Shares

Institutional Holding

0.02%

ROCE (avg)

10.32%

ROE (avg)

8.16%

Valuation key factors

Factor

Value

P/E Ratio

NA (Loss Making)

Industry P/E

Price to Book Value

0.20

EV to EBIT

-17.92

EV to EBITDA

-20.11

EV to Capital Employed

0.15

EV to Sales

28.32

PEG Ratio

Dividend Yield

ROCE (Latest)

-0.85%

ROE (Latest)

-0.70%

Technicals key factors

Indicator

Weekly

Monthly

MACD

Bearish

RSI

No Signal

Bollinger Bands

Bearish

Moving Averages

Bearish (Daily)

KST

Bearish

Dow Theory

Bearish

No Trend

OBV

Mildly Bearish

Technical Indicator Scale: Bearish, Mildly Bearish, Sideways, Mildly Bullish, Bullish Turned

Shareholding

Shareholding Snapshot : Dec 2014

Shareholding Compare (%holding)

Majority shareholders

Foreign Institutions

Domestic Funds

Held in 0 Schemes (0%)

Foreign Institutions

Held by 1 Foreign Institutions (0.02%)

Strategic Entities with highest holding

Highest Public shareholder

Financial

[
  {
    "link": "quarterly",
    "btn_text": "All Quarterly Results",
    "header": "Quarterly Results Snapshot (Consolidated) - Sep'25 - QoQ",
    "rhs": [
      {
        "prefix": "Net Sales ",
        "suffix": "QoQ Growth in quarter ended Sep 2025 is -25.81% vs -34.04% in Jun 2025",
        "dir": 1
      },
      {
        "prefix": "Consolidated Net Profit ",
        "suffix": "QoQ Growth in quarter ended Sep 2025 is 8.87% vs -416.20% in Jun 2025",
        "dir": 1
      }
    ],
    "table": {
      "header": [
        "Sep'25",
        "Jun'25",
        "Change(%)"
      ],
      "body": [
        {
          "field": "Net Sales",
          "val1": "2.30",
          "val2": "3.10",
          "chgp": "-25.81%",
          "chgp_class": "negative"
        },
        {
          "field": "Operating Profit (PBDIT) excl Other Income",
          "val1": "-66.60",
          "val2": "-73.10",
          "chgp": "8.89%",
          "chgp_class": "positive"
        },
        {
          "field": "Interest",
          "val1": "0.00",
          "val2": "0.00",
          "chgp": "",
          "chgp_class": "neutral"
        },
        {
          "field": "Exceptional Items",
          "val1": "0.00",
          "val2": "0.00",
          "chgp": "",
          "chgp_class": "neutral"
        },
        {
          "field": "Consolidate Net Profit",
          "val1": "-66.80",
          "val2": "-73.30",
          "chgp": "8.87%",
          "chgp_class": "positive"
        },
        {
          "field": "Operating Profit Margin (Excl OI)",
          "val1": "-29,662.40%",
          "val2": "-23,857.60%",
          "chgp": "-580.48%",
          "chgp_class": "negative"
        }
      ]
    }
  },
  {
    "link": "annual",
    "btn_text": "All Annual Results",
    "header": "Annual Results Snapshot (Consolidated) - Dec'24",
    "rhs": [
      {
        "prefix": "Net Sales ",
        "suffix": "YoY Growth in year ended Dec 2024 is 107.14% vs -9.68% in Dec 2023",
        "dir": 1
      },
      {
        "prefix": "Consolidated Net Profit ",
        "suffix": "YoY Growth in year ended Dec 2024 is -250.00% vs 106.13% in Dec 2023",
        "dir": -1
      }
    ],
    "table": {
      "header": [
        "Dec'24",
        "Dec'23",
        "Change(%)"
      ],
      "body": [
        {
          "field": "Net Sales",
          "val1": "5.80",
          "val2": "2.80",
          "chgp": "107.14%",
          "chgp_class": "positive"
        },
        {
          "field": "Operating Profit (PBDIT) excl Other Income",
          "val1": "-8.20",
          "val2": "-1.10",
          "chgp": "-645.45%",
          "chgp_class": "negative"
        },
        {
          "field": "Interest",
          "val1": "0.10",
          "val2": "0.00",
          "chgp": "",
          "chgp_class": "neutral"
        },
        {
          "field": "Exceptional Items",
          "val1": "0.00",
          "val2": "0.00",
          "chgp": "",
          "chgp_class": "neutral"
        },
        {
          "field": "Consolidate Net Profit",
          "val1": "-8.10",
          "val2": "5.40",
          "chgp": "-250.00%",
          "chgp_class": "negative"
        },
        {
          "field": "Operating Profit Margin (Excl OI)",
          "val1": "-1,580.30%",
          "val2": "-680.80%",
          "chgp": "-89.95%",
          "chgp_class": "negative"
        }
      ]
    }
  }
]

Quarterly Results Snapshot (Consolidated) - Sep'25 - QoQ

Sep'25

Jun'25

Change(%)

Net Sales

2.30

3.10

-25.81%

Operating Profit (PBDIT) excl Other Income

-66.60

-73.10

8.89%

Interest

0.00

Exceptional Items

0.00

Consolidate Net Profit

-66.80

-73.30

8.87%

Operating Profit Margin (Excl OI)

-29,662.40%

-23,857.60%

-580.48%

USD in Million.

Compare with Peers

Net Sales

QoQ Growth in quarter ended Sep 2025 is -25.81% vs -34.04% in Jun 2025

Consolidated Net Profit

QoQ Growth in quarter ended Sep 2025 is 8.87% vs -416.20% in Jun 2025

All Quarterly Results

Annual Results Snapshot (Consolidated) - Dec'24

Dec'24

Dec'23

Change(%)

Net Sales

5.80

2.80

107.14%

Operating Profit (PBDIT) excl Other Income

-8.20

-1.10

-645.45%

Interest

0.10

0.00

Exceptional Items

0.00

Consolidate Net Profit

-8.10

5.40

-250.00%

Operating Profit Margin (Excl OI)

-1,580.30%

-680.80%

-89.95%

USD in Million.

Compare with Peers

Net Sales

YoY Growth in year ended Dec 2024 is 107.14% vs -9.68% in Dec 2023

Consolidated Net Profit

YoY Growth in year ended Dec 2024 is -250.00% vs 106.13% in Dec 2023

All Annual Results

Company CV

About Karolinska Development AB

Karolinska Development AB

Finance

Karolinska Development AB is a Sweden-based investment company. The Company provides capital to biotechnology firms, as well as develops and commercializes biotechnological products. Its activities are involved in a range of areas: oncology, infections and wound healing, women’s health, cardiovascular and hematology, medical equipment, diagnostics, pharmaceutical formulation, as well as implants, among others. The Company’s pharmaceuticals portfolio comprises: AXL1717 for non-small-cell lung carcinoma (NSCLC), APR-246 for ovarian cancer, Sevuparin for malaria, SHACT for pain relief at hysteroscopy and intrauterine device (IUD) insertion, and PC-mAB for acute coronary syndrome (ACS), among others. Furthermore, the Company controls a number of subsidiaries, such as Avaris AB, HBV Thernostica AB, KD Incentive AB, KDev Oncology AB and Limone AB.

Company Coordinates

Company Details

Tomtebodavagen 23 A , SOLNA None : 171 65

Tel: 46 8 52486070

http://www.karolinskadevelopment.com/

Registrar Details